Material event report (equity acquisition)

What happened

Decision to Acquire Equity and Equity-Linked Securities of Another Company 6.0 CXI Healthcare Technology Group Limited Material Event Report / Korea Exchange Disclosure Obligation To: Financial Services Commission / Korea Exchange July 15, 2026 Company name: CXI Healthcare Technology Group Limited CEO: LIN JIN SHENG Head office address: Third Floor, Century Yard, Cricket Square, P.O. Box 902, Grand Cayman, KY1-1103, Cayman Islands Phone: 86-591-8803-1033 Website: http://cxihealthcare.com Preparer: Disclosure Officer, LIN HANGHAN, Phone: 02-782-0560 (contact of the disclosure agent)

Decision to Acquire Equity and Equity-Linked Securities of Another Company

1. Issuing Company Company name: Fujian Yingshenghuoli Bio-Engineering Co., Ltd. Nationality: China Representative: CHEN ZHEN Capital (KRW): 1,891,600,000 Relationship with the company: Subsidiary Total shares issued: - Main business: Manufacture and sale of health supplements Whether shares were acquired through third-party allotment within the last 6 months: No

2. Acquisition Details Number of shares to be acquired: - Acquisition amount (KRW) (A): 313,153,708,470 Total assets (KRW) (B): 494,176,463,326 A/B ratio (%): 63.37 Equity capital (KRW) (C): 491,642,280,374 A/C ratio (%): 63.70

3. Shares Owned and Equity Ratio After Acquisition Shares owned: - Equity ratio (%): 100

4. Purpose of Acquisition: To improve management efficiency and decision-making through restructuring of the governance structure

5. Scheduled Acquisition Date: August 31, 2026

6. Counterparty Company name (name): Zhejiang Dingsheng Health Technology Group Co., Ltd. Capital (KRW): 84,100,536,000 Main business: Investment Head office address: Fuzhou, Fujian, China Relationship with the company: Subsidiary

7. Payment of Transaction Price: No consideration; transfer without payment of a transaction price

8. External Valuation Whether an external valuation was obtained: Yes Basis and reason: (1) Basis: Appropriateness evaluation under Article 161 of the Financial Investment Services and Capital Markets Act and Article 171 of its Enforcement Decree. (2) Reason: Used as reference material to assess the appropriateness of the asset transfer price, and as an attachment to the material event report. External valuation firm: Induk Accounting Corporation External valuation period: May 1, 2026 - June 24, 2026 External valuation opinion: The appraiser applied the discounted cash flow (DCF) method to value the company being valued. Based on the appraiser's analysis described in this opinion letter, the appraised value of the company being valued as of the valuation date was estimated to range from a minimum of CNY 1,423,879 thousand to a maximum of CNY 2,008,006 thousand. However, as the equity transfer transaction between your company and the transferor for the company being valued is structured as a no-consideration transfer, it does not fall within the range the appraiser considered appropriate.

9. Board resolution date (decision date): July 15, 2026 Attendance of outside directors: Present: -; Absent: - Attendance of the auditor (audit committee member who is not an outside director): Present

10. Whether this constitutes a backdoor listing: No Plans for third-party allotment capital increase etc. within the next 6 months: No

11. Whether the issuing company (the other company) meets the requirements for a backdoor listing: No

12. Whether subject to reporting to the Fair Trade Commission: Not applicable

13. Whether a put option or similar contract was entered into: No Contract details: -

14. Future Plans for Corporate Restructuring: Before completion of this transaction, the issuing company, Fujian Yingshenghuoli Bio-Engineering Co., Ltd., is a sub-subsidiary of the company, wholly owned (100%) by the company's subsidiary, Zhejiang Dingsheng Health Technology Group Co., Ltd. After completion of this transaction, the company will directly hold 100% of the issuing company, and the issuing company will accordingly move from being the company's sub-subsidiary to being a direct subsidiary. This transaction is intended to improve management efficiency and decision-making through restructuring of the governance structure within the same consolidated group.

15. Other Material Matters Relevant to Investment Decisions 1) This transaction is a no-consideration transfer for governance restructuring within the same consolidated group, and involves no separate cash inflow or outflow. The external valuation institution's results are reference material on the economic value of the equity being acquired; because this transaction is structured as a no-consideration transfer, the valuation range and the transaction price do not match. 2) The capital of a Chinese "youxian gongsi" (limited liability company) is not divided into shares (accordingly, there is no concept of number of shares or par value); shareholders instead hold an interest corresponding to the paid-in capital they contributed (the Korean equivalent of paid-in capital). Accordingly, this disclosure does not state a number of shares or par value. 3) The "1. Issuing company's capital" above is prepared based on the separate (non-consolidated) financial statements as of the end of the most recent fiscal year (June 2025), applying the exchange rate of KRW 189.16/CNY first quoted by Seoul Money Brokerage Services Ltd. on June 30, 2025, to the issuing company's capital of CNY 10,000,000. 4) In "2. Acquisition Details" above, the company's "total assets" and "equity capital" are prepared based on the consolidated financial statements as of the end of the most recent fiscal year, applying the exchange rate of KRW 189.16/CNY quoted by Seoul Money Brokerage Services Ltd. on June 30, 2025, to the company's total assets of CNY 2,612,478,660 and equity capital of CNY 2,599,081,626. 5) The "2. Acquisition amount (KRW)" above applies the exchange rate of KRW 219.93/CNY quoted by Seoul Money Brokerage Services Ltd. as of the base date of July 15, 2026, to the valuation amount of CNY 1,423,879,000. 6) The "5. Scheduled Acquisition Date" above is based on the expected date of receipt of the registration documents for completion of the no-consideration transfer, and may change depending on the processing schedule of local authorities. 7) The "6. Counterparty's capital" above is prepared as of the end of the most recent fiscal year (June 2025), applying the exchange rate of KRW 189.16/CNY quoted by Seoul Money Brokerage Services Ltd. on June 30, 2025, to the counterparty's capital of CNY 444,600,000. Related disclosures: None.

[Summary Financial Status of the Issuing Company] (Unit: KRW million) Current year: Total assets 454,737; Total liabilities 115,795; Total equity 338,942; Capital 1,892; Revenue 53,842; Net income 10,894; Audit opinion -; External auditor - Prior year: Total assets 448,232; Total liabilities 117,706; Total equity 330,526; Capital 1,904; Revenue 67,520; Net income 20,904; Audit opinion -; External auditor - Year before that: Total assets 389,758; Total liabilities 96,062; Total equity 293,696; Capital 1,811; Revenue 70,508; Net income 10,121; Audit opinion -; External auditor - * The above summary financial status of the issuing company is translated into Korean won, using the period-end exchange rate for balance-sheet items and the average exchange rate for income-statement items for each period (as quoted by Seoul Money Brokerage Services Ltd.). Note 1) Current year (2025) period-end exchange rate: KRW 189.16/CNY; average exchange rate: KRW 194.05/CNY. Note 2) Prior year (2024) period-end exchange rate: KRW 190.43/CNY; average exchange rate: KRW 184.17/CNY. Note 3) Year before that (2023) period-end exchange rate: KRW 181.05/CNY; average exchange rate: KRW 189.95/CNY. * Based on unaudited financial statements.

[Matters Concerning the Counterparty] 1. Personal Details - Basic Information Name: Zhejiang Dingsheng Health Technology Group Co., Ltd.; Nationality: China; Address (head office) [district/town/dong only]: Fuzhou, Fujian, China; Occupation (business description): Investment Status and financial condition of the largest shareholder, CEO, and representative executive officer (if the counterparty is a corporation): CEO: SUN SHUANGYI (Sun Shuangyi); Shares -; Equity ratio (%) - (Unit: KRW million) Most recent fiscal year: fiscal year 2025; Fiscal year-end: June; Total assets: 111,719; Capital: 84,101; Total liabilities: 12,589; Revenue: 0; Total equity: 99,130; Net income/loss: -2,632; External auditor -; Suspension of business: No; Audit opinion -; Business closure: No 2. Relationship with the Company or Its Largest Shareholder/Officers Relationship between the company and the counterparty: Largest shareholder itself Relationship between the company's largest shareholder/officers and the counterparty: Name: LIN JINSHENG (as stated in the filing); Relationship with counterparty: Largest shareholder; Name: LIN JINSHENG (as stated in the filing); Relationship with counterparty: CEO 3. Transactions in the Last 3 Years (excluding routine transactions) Current year: -; Prior year: -; Year before that: -